This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
by Zacks Equity Research
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
CRMDNegative Net Change KNSAPositive Net Change PHARNegative Net Change RAPPPositive Net Change
biotechnology biotechs medical pharmaceuticals
OLMA Stock Soars 47% in September So Far on Second PFE Deal
by Zacks Equity Research
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
AZNNegative Net Change NVSNegative Net Change PFENegative Net Change OLMANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
by Sundeep Ganoria
ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
by Ekta Bagri
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
by Ekta Bagri
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
by Zacks Equity Research
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
SNYNegative Net Change ABBVNegative Net Change RGNXNegative Net Change FDMTNegative Net Change
biotechs medical pharmaceuticals
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
by Zacks Equity Research
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
CRMDNegative Net Change KNSAPositive Net Change TVTXNegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Where Does VKTX Stock Stand After the Obesity Pill Setback?
by Sundeep Ganoria
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
by Zacks Equity Research
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
RHHBYNegative Net Change BMYNegative Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
by Ekta Bagri
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
by Zacks Equity Research
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
NVSNegative Net Change NVOPositive Net Change ARWRNo Net Change TRMLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
by Zacks Equity Research
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
BMYNegative Net Change MRKNegative Net Change SMMTPositive Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
RARENegative Net Change CRMDNegative Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
RDYNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechs medical
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
by Ahan Chakraborty
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
ALNYNegative Net Change PFENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Leveraged ETF Areas of Last Week That Are Up At least 15%
by Sanghamitra Saha
Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.
AVGOPositive Net Change GOOGLPositive Net Change LABUNegative Net Change JNUGNegative Net Change AVGGPositive Net Change GDXUPositive Net Change GGLLPositive Net Change GOOXPositive Net Change AVGXPositive Net Change SOUXNegative Net Change
biotechs etfs
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
by Ekta Bagri
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
by Zacks Equity Research
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
REGNNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
by Zacks Equity Research
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
AGIOPositive Net Change ADPTNegative Net Change ALLONegative Net Change AKRONegative Net Change
biotechs
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
by Zacks Equity Research
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
CRMDNegative Net Change KNSAPositive Net Change IMVTNegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
by Zacks Equity Research
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
AZNNegative Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?
by Sundeep Ganoria
ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.
BIIBNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
by Zacks Equity Research
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
UTHRPositive Net Change INSMPositive Net Change LQDANegative Net Change
biotechs medical